Premorbid lipid levels and long-term risk of ALS—a population-based cohort study

References

• Jésus P, Fayemendy P, Nicol M, Lautrette G, Sourisseau H, Preux PM, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2018;25:97–104.
   PubMed Web of Science ®Google Scholar
• Steyn FJ, Ioannides ZA, van Eijk RPA, Heggie S, Thorpe KA, Ceslis A, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018;89:1016–23.
   PubMed Web of Science ®Google Scholar
• Ahmed RM, Highton-Williamson E, Caga J, Thornton N, Ramsey E, Zoing M, et al. Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behavior and cognition. J Alzheimers Dis. 2018;61:773–83.
   PubMed Web of Science ®Google Scholar
• Huang R, Guo X, Chen X, Zheng Z, Wei Q, Cao B, et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:359–65.
   PubMed Web of Science ®Google Scholar
• Ingre C, Chen L, Zhan Y, Termorshuizen J, Yin L, Fang F. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology 2020;94:e1835–e44.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Rosi E, Fini N, Fasano A, Raggi S, Fantuzzi AL, et al. Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis. Neurol Sci. 2017;38:2177–82.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258:613–7.
   PubMed Web of Science ®Google Scholar
• Michels S, Kurz D, Rosenbohm A, Peter RS, Just S, Bäzner H, et al. Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registry. J Neurol. 2023;270:3082–90.
   PubMed Web of Science ®Google Scholar
• Barone M, Viggiani MT, Introna A, D'Errico E, Scarafino A, Iannone A, et al. Nutritional prognostic factors for survival in amyotrophic lateral sclerosis patients undergone percutaneous endoscopic gastrostomy placement. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:490–6.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;45: 612–24.
   Google Scholar
• Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:478–84.
   PubMed Web of Science ®Google Scholar
• Janse van Mantgem MR, van Rheenen W, Hackeng AV, van Es MA, Veldink JH, van den Berg LH, et al. Association between serum lipids and survival in patients with amyotrophic lateral sclerosis: a meta-analysis and population-based study. Neurology 2023;100:e1062–e71.
   PubMed Web of Science ®Google Scholar
• Mariosa D, Hammar N, Malmström H, Ingre C, Jungner I, Ye W, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017;81:718–28.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Talbot K, Turner MR. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022;93:75–81.
   PubMed Web of Science ®Google Scholar
• Bjornevik K, O'Reilly ÉJ, Cortese M, Furtado JD, Kolonel LN, Le Marchand L, et al. Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:133–43.
   PubMedGoogle Scholar
• van Rheenen W, van der Spek RAA, Bakker MK, van Vugt J, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53:1636–48.
   PubMed Web of Science ®Google Scholar
• Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67:202.e1–e6.
   PubMed Web of Science ®Google Scholar
• Xia K, Klose V, Högel J, Huang T, Zhang L, Dorst J, et al. Lipids and amyotrophic lateral sclerosis: a two-sample Mendelian randomization study. Eur J Neurol. 2023;30:1899–906.
   PubMed Web of Science ®Google Scholar
• Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28:688–97.
   PubMed Web of Science ®Google Scholar
• Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85:470–81.
   PubMed Web of Science ®Google Scholar
• Esteban-García N, Fernández-Beltrán LC, Godoy-Corchuelo JM, Ayala JL, Matias-Guiu JA, Corrochano S. Body complexion and circulating lipids in the risk of TDP-43 related disorders. Front Aging Neurosci. 2022;14:838141.
   PubMed Web of Science ®Google Scholar
• Benatar M, Granit V, Andersen PM, Grignon AL, McHutchison C, Cosentino S, et al. Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity. Brain. 2022;145:3500–8.
   PubMed Web of Science ®Google Scholar
• Muga MA, Owili PO, Hsu CY, Chao JC. Association of lifestyle factors with blood lipids and inflammation in adults aged 40 years and above: a population-based cross-sectional study in Taiwan. BMC Public Health. 2019;19:1346.
   PubMed Web of Science ®Google Scholar
• Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000;8:605–19.
   PubMedGoogle Scholar
• Parhofer KG. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J. 2015;39:353–62.
   PubMed Web of Science ®Google Scholar
• Zhan Y, Fang F. Smoking and amyotrophic lateral sclerosis: a mendelian randomization study. Ann Neurol. 2019;85:482–4.
   PubMed Web of Science ®Google Scholar
• Nakken O, Meyer HE, Stigum H, Holmøy T. High BMI is associated with low ALS risk: a population-based study. Neurology 2019;93:e424–e32.
   PubMed Web of Science ®Google Scholar
• Fang F, Hållmarker U, James S, Ingre C, Michaëlsson K, Ahlbom A, et al. Amyotrophic lateral sclerosis among cross-country skiers in Sweden. Eur J Epidemiol. 2016;31:247–53.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tang L, Huang T, Fan D. Association between type 2 diabetes and amyotrophic lateral sclerosis. Sci Rep. 2022;12:2544.
   PubMed Web of Science ®Google Scholar
• Foss O, Urdal P. Cholesterol for more than 25 years: could the results be compared throughout all this time? Nor Epidemiol 2003;13:85–8.
   Google Scholar
• Selmer R, Tverdal A. Serum total cholesterol and mortality from ischaemic heart disease, all cardiovascular causes and all causes: 25-year follow-up of the first cardiovascular screening in Finnmark, Oppland and Sogn og Fjordane. Nor J Epidemiol 2003;13:115–25.
   Google Scholar
• Norwegian Institute of Public Health. 40 årsundersøkelsene (1985–1999) [Online] [updated 2019 Jun 16; cited 2023 May 19]. 2013. Available at: https://www.fhi.no/div/helseundersokelser/landsomfattende-helseundersokelser-lhu/helseundersokelser/40-aringsundersokelsene/.
   Google Scholar
• Tverdal A, Hjellvik V, Selmer R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40–45 years. Eur Heart J. 2008;29:2772–81.
   PubMed Web of Science ®Google Scholar
• Naess O, Søgaard AJ, Arnesen E, Beckstrøm AC, Bjertness E, Engeland A, et al. Cohort profile: cohort of Norway (CONOR). Int J Epidemiol. 2008;37:481–5.
   PubMed Web of Science ®Google Scholar
• Higgins V, Leiter LA, Delaney SR, Beriault DR. Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up? Clin Biochem. 2022;99:60–8.
   PubMed Web of Science ®Google Scholar
• Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5:540–8.
   PubMed Web of Science ®Google Scholar
• SI Units Conversion Table. Ann Pharmacother. 1996;30:96–103.
   Google Scholar
• Nakken O, Lindstrøm JC, Tysnes O-B, Holmøy T. Mortality trends of amyotrophic lateral sclerosis in Norway 1951–2014: an age-period-cohort study. J Neurol. 2016;263:2378–85.
   PubMed Web of Science ®Google Scholar
• Nakken O, Lindstrøm JC, Tysnes O-B, Holmøy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:303–10.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Marsden R, Talbot K, Turner MR. Primary care blood tests show lipid profile changes in pre-symptomatic amyotrophic lateral sclerosis. Brain Commun. 2023;5:fcad211.
   PubMedGoogle Scholar
• Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;14:577–90.
   PubMed Web of Science ®Google Scholar
• Bjornevik K, O'Reilly EJ, Molsberry S, Kolonel LN, Le Marchand L, Paganoni S, et al. Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology 2021;97:e1466-74–e74.
   Web of Science ®Google Scholar
• Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72:905–11.
   PubMed Web of Science ®Google Scholar
• Mitra S, Deshmukh A, Sachdeva R, Lu J, Mehta JL. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci. 2011;342:135–42.
   PubMed Web of Science ®Google Scholar
• Xiong L, McCoy M, Komuro H, West XZ, Yakubenko V, Gao D, et al. Inflammation-dependent oxidative stress metabolites as a hallmark of amyotrophic lateral sclerosis. Free Radic Biol Med. 2022;178:125–33.
   PubMed Web of Science ®Google Scholar
• Fernandez ML, West KL. Mechanisms by which dietary fatty acids modulate plasma lipids. J Nutr. 2005;135:2075–8.
   PubMed Web of Science ®Google Scholar
• Xia K, Wang Y, Zhang L, Tang L, Zhang G, Huang T, et al. Dietary-derived essential nutrients and amyotrophic lateral sclerosis: a two-sample Mendelian randomization study. Nutrients 2022;14:920.
   PubMed Web of Science ®Google Scholar
• O'Reilly ÉJ, Bjornevik K, Furtado JD, Kolonel LN, Le Marchand L, McCullough ML, et al. Prediagnostic plasma polyunsaturated fatty acids and the risk of amyotrophic lateral sclerosis. Neurology 2020;94:e811–e9.
   PubMed Web of Science ®Google Scholar
• Ho WY, Chang JC, Lim K, Cazenave-Gassiot A, Nguyen AT, Foo JC, et al. TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination. J Cell Biol 2021;220:e201910213
   PubMed Web of Science ®Google Scholar
• Mariosa D, Kamel F, Bellocco R, Ronnevi LO, Almqvist C, Larsson H, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:1010–6.
   PubMed Web of Science ®Google Scholar
• Norwegian Institute of Public Health. CONOR: Research potential, design and representativeness [Online] [cited 2023 Nov 2]. 2013. Available at: https://www.fhi.no/globalassets/dokumenterfiler/studier/conor/conor.pdf.
   Google Scholar
• Statistics Norway. Educational attainment of the population [Online] [cited 2023 Nov 6]. Available at: https://www.ssb.no/en/statbank/table/08921/.
   Google Scholar
• Marin B, Couratier P, Preux PM, Logroscino G. Can mortality data be used to estimate amyotrophic lateral sclerosis incidence? Neuroepidemiology 2011;36:29–38.
   PubMed Web of Science ®Google Scholar
• Benjaminsen E, Alstadhaug KB, Gulsvik M, Baloch FK, Odeh F. Amyotrophic lateral sclerosis in Nordland county, Norway, 2000–2015: prevalence, incidence, and clinical features. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:522–7.
   PubMed Web of Science ®Google Scholar